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Received February 6, 2012; accepted August 27, 2012AbstractBackground: Rituximab-containing salvage chemotherapy has shown promising efficacy in patients with relapsed/refractory B-cell non-
Hodgkin’s lymphoma (NHL). The aim of this study was to examine the efficacy of rituximab-containing treatment in patients with B-cell NHL
who developed relapsed or refractory disease after prior rituximab use and to explore the predictive factors of response using this approach.
Methods: Patients with relapsed/refractory B-cell NHL who received rituximab-containing salvage treatment after failing first-line rituximab-
combining chemotherapy were enrolled in this retrospective study. The characteristics of the patients were collected and analyzed. Logistic
regression analysis was used for determining predictive factors of response to rituximab-containing salvage treatment.
Results: A total of 68 patients were enrolled in this study and the overall response rate to rituximab-containing salvage treatment was 61.7%. The
median event-free survival and overall survival with rituximab-containing salvage treatment was 11.3 and 21.73 months, respectively. Results of
a multivariate analysis showed high absolute lymphocyte count at the time of rituximab-containing salvage treatment [(ALC-R), ALC-R  1000/
UL, p ¼ 0.003)], which was the only independent factor predicting response to rituximab-containing salvage treatment.
Conclusion: Our study results show that for patients with relapsed/refractory B-cell NHL, rituximab-containing salvage treatment is feasible and
generally tolerable. A high ALC-R value was significantly associated with a better response to this treatment.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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The combination of rituximab, a chimeric monoclonal anti-
CD 20 antibody, with chemotherapeutics has significantly
improved therapy for B-cell non-Hodgkin’s lymphoma
(NHL).1 The addition of rituximab improves the overall* Corresponding author. Dr. Chun-Yu Liu, Division of Haematology and
Oncology, Department of Medicine, Taipei Veterans General Hospital, 201,
Section 2, Shih-Pai Road, Taipei 112, Taiwan, ROC.
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http://dx.doi.org/10.1016/j.jcma.2012.12.003response rate (ORR) and survival of patients with B-cell
NHL.2e5 Frontline rituximab combined with cyclo-
phosphamide, hydroxydaunorubicin, vincristine, and prednis-
olone (R-CHOP) or other rituximab-combination regimens
have become the standard therapy for most patients with
B-cell NHL.6
Despite this significant progress, more than half of the
patients with B-cell NHL still develop relapse or progressive
disease (PD).7 Salvage therapy for these patients with prior
rituximab exposure can be challenging, particularly for those
with aggressive B-cell NHL.8,9 One promising approach tohinese Medical Association. All rights reserved.
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well established involves the re-introduction of rituximab to
dose-intensive salvage regimens.8,10e14 However, only limi-
ted data are available in published prospective trials, which
address rituximab-containing salvage treatment in patients
with relapsed/refractory B-cell NHL.10,14 Davis et al dem-
onstrated an ORR of 40% to rituximab monotherapy in pa-
tients with relapsed low-grade B-cell NHL.10 In the
Collaborative Trial in Relapsed Aggressive Lymphoma
(CORAL) study, Gisselbrecht et al compared the efficacy of
rituximab, ifosfamide, etoposide, and carboplatin (R-ICE)
with rituximab, dexamethasone, high-dose cytarabine, and
cisplatin (R-DHAP) before autologous stem cell trans-
plantation in patients with relapsed/refractory diffuse large
B-cell lymphoma (DLBCL), and demonstrated an ORR of
51% to rituximab-containing salvage treatment in patients
with prior rituximab exposure.14 Previous retrospective trials
have suggested that intensive chemotherapy combined with
rituximab, as second-line treatment for relapsed/refractory
DLBCL, was an effective method with a reported ORR of
approximately 66%.8,12
However, the varied patient response to rituximab-
containing salvage treatment reported in previously published
data and the factors associated with patient response remain to
be elucidated. To date, only the Grupo Espan˜ol de Linfomas/
Trasplante de Me´dula Osea (GEL/TAMO) study8 and the
CORAL study14 have suggested several factors including
a high age-adjusted International Prognostic Index (IPI) score,
primary refractory disease, and short relapse-free duration,
which may influence the response to rituximab-containing
salvage treatment. However, the conclusions they reached are
limited in their application to patients with DLBCL receiving
certain rituximab-containing regimens (R-ICE, R-DHAP, and
rituximab, etoposide, methylprednisolone, cytarabine and cis-
platin (R-ESHAP)). For patients with relapsed/refractory B-
cell NHL, other than DLBCL, only limited are data available on
the significant factors that predict response to rituximab-
containing salvage treatment. Therefore, the aim of this study
was to re-examine its efficacy and to explore the predictive
factors of response to rituximab-containing salvage treatment
in patients who previously received rituximab.
2. Methods2.1. PatientsWe first identified patients with pathologically confirmed
B-cell NHL that received first-line rituximab-combination
regimens, during the period from January 2003 to January
2010. Among these patients, those who received rituximab-
containing salvage treatment for relapsed/refractory disease
were enrolled for the analysis. The demographic data and
clinical characteristics of the study population were obtained
from clinical chart review, lymphoma registry information,
and physician records, as previously described.15 The Insti-
tutional Review Board of Taipei Veterans General Hospital
approved this retrospective study.2.2. Rituximab for first-line treatment and salvage
treatment and response criteriaThe dose of rituximab, either for frontline combination
treatment or in the salvage setting, was 375 mg/m2 on day 1 of
each treatment cycle. The choice of salvage regimens, with
rituximab, was on an individualized basis at the discretion of
the attending physicians. The response criteria used for
a complete response (CR), partial response (PR), and PD were
according to the International Workshop Criteria16 and were
prospectively determined during the course of treatment and
retrospectively reviewed for this study. Patients who achieved
a CR or PR to rituximab-containing chemotherapy were
defined as responders.2.3. Statistical methodsEvent-free survival, with rituximab-containing salvage
treatment (EFS-r), was calculated from the date of starting
rituximab-containing salvage treatment to the date of disease
progression, date of the next treatment, death, or the date of
the last consultation. The overall survival after rituximab-
containing salvage treatment (OS-r) was calculated from the
date of starting rituximab-containing salvage treatment to the
date of death or the date of the last consultation. EFS-r and
OS-r were estimated using the KaplaneMeier method and
were compared by the logrank test. Categorical variables were
compared by the Chi-square or Fisher exact tests as appro-
priate. The absolute lymphocyte count (ALC) was calculated
as the total while cell counts multiplied by the percent lym-
phocyte, and lymphopenia was defined as an ALC < 1000/mL.
The paired t test was used for comparing the ALC at the time
of the diagnosis of lymphoma with the ALC at the time of
rituximab-containing salvage treatment (ALC-R). The possi-
ble factors associated with response to rituximab-containing
salvage treatment were evaluated using univariate and multi-
variate logistic regression models. Variables with p < 0.10 on
the univariate analyses were used for the multivariate analyses.
A p value < 0.05 was regarded as statistically significant on
the two-tailed tests. All statistical analysis was computed
using SPSS software (version 17.0; SPSS, Inc., Chicago, IL,
USA).
3. Results3.1. Patients’ characteristicsFrom January 2003 to September 2010, a total of 315 pa-
tients with B-cell NHL were treated with first-line rituximab-
containing treatments at the Taipei Veterans General Hospital.
Among these patients, 68 (21.6%) received rituximab-
containing salvage treatment for relapsed/refractory disease
and were enrolled in this retrospective study. Table 1 lists the
characteristics of these 68 patients at the time of rituximab-
containing salvage treatment. Male gender, old age (>60
years of age), advanced stage disease (Ann Arbor stages III
and IV), aggressive histological subtypes (DLBCL plus mantle
Table 1
Characteristics of patients at the time of rituximab-containing salvage
treatment.
Characteristics Number (n ¼ 68) %
Histology subtype
Diffuse large B-cell lymphoma 52 76.5
Mantle cell lymphoma 4 5.9
Follicular lymphoma 12 17.6
Gender
Male 48 70.6
Female 20 29.4
Age (y)
Median (range) 63 (18e85) d
Older than 60 37 54.4
Ann Arbor stage
IeII 26 38.2
IIIeIV 42 61.8
Bone marrow involvement 4 5.9
No. of prior treatment lines
1 62 91.2
>2 6a 8.8
Prior rituximab exposure, cycles
Median (range) 5.5 (1e11) d
Time between first-line treatment and rituximab retreatment (mo)
Median (range) 6.1 (1e54) d
Retreatment < 1 y 45 66.2
IPI-Rb
0e2 30 44.1
3e5 38 55.9
ALC-Rc/mL
Median (range) 959.5 (180e2982) d
<1000 36 51.9%
a Four patients received two lines and two patients received three lines of
treatment before starting rituximab-containing salvage treatment.
b International Prognostic Index score at the time of rituximab-containing
salvage treatment.
c Absolute lymphocyte count at the time of rituximab-containing salvage
treatment.
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containing salvage treatment (IPI-R  2) were the predomi-
nant characteristics of the study group. There were only four
(5.9%) patients received this salvage strategy at the third-line
setting, and two (2.9%) as a fourth-line treatment. Most
patients (91.2%) received rituximab-containing salvage treat-
ment as a second-line treatment, whereas four (5.9%) patients
received rituximab as a third-line, and two (2.9%) as a fourth-
line treatment. Notably, the ALC-R was lower than at the time
of lymphoma diagnosis (median 959.5/mL vs. 1323/mL,
p ¼ 0.045). In addition, the proportion of patients with lym-
phopenia was higher at the time of rituximab-containing
treatment (51.1% vs. 33.8%, p ¼ 0.011).3.2. Rituximab-containing salvage treatment regimenAll study patients received rituximab in combination with
chemotherapy in the salvage setting. The regimens used were
the following: ESHAP (n ¼ 36, 52.9%), ICE (n ¼ 12, 17.6%),
CHOP (n ¼ 11, 16.2%), fludarabine (n ¼ 3, 4.4%), and others
(n ¼ 6, 8.8%). The median cycles of rituximab used in the
salvage setting was three (range: 1e16).3.3. Peripheral blood stem cell transplantationFifteen patients (22.1%) received peripheral blood stem cell
transplants (PBSCT) during the study period. Of the 15 pa-
tients, 12 received autologous PBSCT following rituximab-
containing salvage treatment; eight (66.7%) achieved a CR
and were considered to have a long-term disease-free status at
the last follow-up, whereas the remaining four (33.3%) pa-
tients had either progression of the disease or severe sepsis
after PBSCT. The other three patients who received rituximab-
containing salvage treatment ultimately failed salvage PBSCT
for relapsed disease (one relapsed after autologous PBSCT and
two after allogeneic PBSCT). One of these three patients
survived after rituximab-containing salvage treatment.3.4. Rituximab-containing salvage treatment response
and safetyThe ORR to rituximab-containing salvage treatment was
61.7%, which included 19 patients (27.9%) who achieved
a CR, and 23 patients (33.8%) who achieved a PR.
Compared with patients with follicular lymphoma, pa-
tients with aggressive disease, including DLBCL and mantle
cell lymphoma, had a slightly lower ORR to rituximab-
containing salvage treatment (60.7% vs. 66.7%, p ¼ 0.24).
However, the difference observed in the ORR did not reach
statistical significance. Furthermore the duration between the
first and the second rituximab exposure (longer and shorter
than 1 year) did not have a significant impact on ORR to the
rituximab-containing salvage treatment (65.2% vs. 60.0%,
p ¼ 0.32).
The most commonly observed adverse event was febrile
neutropenia, which occurred in 31 patients (45.6%) during the
salvage treatment period, followed by re-activation of herpes
zoster (14.7%).3.5. Factors associated with response to rituximab-
containing treatmentAs shown in Table 2, a higher ALC-R (ALC  1000/mL),
lower IPI (IPI-R  2), and less-intensive disease involvement
(re-stage 1e2) at the time of rituximab-containing salvage
treatment were univariate factors associated with a better
response to re-treatment. The multivariate analysis showed
that a higher ALC-R was the only independent predictive
factor for response to rituximab-containing salvage treatment.3.6. OS-r and EFS-rThe median EFS-r and OS-r values were 11.3 and 21.73
months, respectively (Fig. 1). Factors that predicted a better
response to rituximab-containing salvage treatment were also
found to be associated with better EFS. For patients with
a lower ALC-R and high IPI-R, the EFS was significantly
poorer ( p ¼ 0.009 for ALC-R and p ¼ 0.001 for IPI-R,
respectively).
Table 2
Factors predicting response to rituximab-containing salvage treatment.
Factor ORR (%) Univariate Multivariate
Odds ratio (95% CI) p Odds ratio (95% CI) p
Gender
Male 60.4 0.82 (0.41e3.6) 0.72 d d
Female 65.0 1 d
Lymphoma subtype
Indolent 66.7 2.09 (0.51e8.57) 0.30 d d
Aggressive 60.7 1 d
IPI-R
0e2 76.7 3.29 (1.14e9.47) 0.028 1.92 (0.59e6.24) 0.28
3e5 50.0 1 1
ALC-R, /mL
1000 81.3 5.42 (1.80e16.35) 0.003 4.61 (1.44e14.73) 0.01
<1000 44.4 1 1
Interval between first-line and salvage setting
12 mo 65.2 1.25 (0.44e3.55) 0.674 d d
<12 mo 60.0 1 d
Prior rituximab dose
5 cycles 63.6 1.17 (0.44e3.11) 0.76 d d
<5 cycles 60.0 1 d
Prior rituximab response
CR/PR 62.1 1.09 (0.28e4.30) 0.90 d d
PD 60.0 1 d
Bone marrow involvement
Yes 75.0 1.89 (0.18e19.29) 0.593 d d
No 61.4 1 d
Age at salvage treatment
<60 68.0 1.64 (0.57e4.70) 0.356 d d
60 56.4 1 d
Stage at salvage treatment
1e2 76.9 3.03 (1.01e9.06) 0.047 2.52 (0.76e8.43) 0.13
3e4 52.4 1 d
ALC-R ¼ absolute lymphocyte count at the time of rituximab-containing salvage treatment; CI ¼ confidence interval; CR ¼ complete response; IPI-
R ¼ International Prognostic Index score at the time of rituximab-containing salvage treatment; ORR ¼ overall response rate; PR ¼ partial response;
PD ¼ progressive disease.
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The goal of this study was to determine the efficacy of
rituximab-containing salvage treatment for patients withFig. 1. KaplaneMeier estimation of event-free survival from rituximab-
containing salvage treatment was 11.3 months.relapsed/refractory B-cell NHL who received first-line ritux-
imab combination therapy. The efficacy of rituximab-
containing salvage treatment was shown by a considerable
CR rate and a favorable ORR (61.7%) in the study patients.
The response rate reported in this study was consistent with
that reported in the literature from Western countries.8,12,13
Moreover, the ALC-R was found to predict response to
rituximab-containing salvage treatment. However, the varied
response to rituximab re-treatment is likely multifactorial.
A better understanding of the relationship between predictive
factors and patient responses may help clinicians to more
effectively undertake individualized patient decision-making
with regard to rituximab re-treatment in patients with
relapsed or refractory B-cell NHL.
The ALC at the time of the diagnosis of lymphoma has
been shown to be an important prognostic factor in patients
with NHL. Lymphopenia at diagnosis has been shown to be
associated with a poor prognosis in patients with NHL.17e19
Patients with DLBCL who complete the standard first-line
R-CHOP treatment and have lymphopenia have been repor-
ted to have a higher risk for relapse as well as a poor prog-
nosis.20,21 However, the prognostic value of ALC after salvage
treatment has not yet been confirmed. The results of this study
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refractory B-cell NHL who receive rituximab-containing sal-
vage treatment after the first-line R-CHOP failure. The asso-
ciation between ALC and response to lymphoma therapy,
particularly to rituximab treatment, might reflect the impor-
tance of an immune system response to lymphoma treatment.
The ALC might be a surrogate marker of the host immune
status,17,19 which the presence of lymphopenia suggests could
be a pre-existing immunosuppressed condition that facilitates
malignant lymphoma cells to escape from immune surveil-
lance.20 In addition, natural killer cells (NK cells) might play
a key role in antibody-dependent cellular cytotoxicity
(ADCC), one of the major mechanisms thought to be involved
in the efficacy of rituximab against lymphoma cells.22 The
depletion of NK cells, resulting from lymphopenia, may lead
to ineffective ADCC, and may be associated with a poor
disease outcome.23,24 Moreover, lymphopenia may also result
from lympholytic cytokines produced by lymphoma cells that
might be consistent with a more aggressive behavior and thus
more resistant to treatment.18 In this study, the predictive and
prognostic values of ALC-R in patients receiving rituximab-
containing salvage treatment were demonstrated. Patients
with a high ALC-R (ALC > 1000/UL) not only had a better
response to rituximab re-treatment (odds ratio ¼ 5.42,
p ¼ 0.003) but also had a better EFS. The findings suggest
a fundamental role of host immunity in NHL and its response
to treatment, particularly in the era of rituximab.
Another prognostic factor for patients with NHLwas the IPI.
IPI at diagnosis25 and relapse26,27 is a well-established scoring
system used to predict survival in patients with lymphoma. In
this study, the IPI-R was significantly associated with EFS after
salvage treatment but not with the response to rituximab-
containing salvage treatment. IPI scores may reflect tumor
aggressiveness, patient response to disease, and tolerability of
intensive therapy25,28; patients with a lower IPI may have less
aggressive lymphoma, which may result in a better outcome.
Interestingly, the prior response to rituximab-containing
treatment, which has been shown to influence the response
to rituximab-containing salvage therapy in the GEL/TAMO
study8 and the CORAL study,14 was not a predictive factor of
response in this study. Possible explanations may be related to
the relatively earlier shift to rituximab in the current study, as
reflected by 55% of the patients receiving rituximab within
a year, and the higher ORR (88.9%) to first-line rituximab
treatment in the patient population enrolled in this study.
Consistent with the results of previous reports,8,12e14 ritux-
imab re-treatment was generally well tolerated, with febrile
neutropenia being the most common adverse event. This might
have been related to the combined salvage chemotherapy.
This study was limited by its retrospective design, the
heterogeneity of the salvage protocols, and a small patient
study group. Moreover, the treatment effect might have mainly
been due to the combination of rituximab and the salvage
chemotherapy. Nevertheless, this study adds useful informa-
tion to the limited available data on rituximab-containing
salvage treatment in patients with relapsed/refractory B-cell
NHL after first-line rituximab combination therapy.In conclusion, rituximab-containing salvage therapy ap-
pears to be a reasonable approach in patients with relapsed/
refractory B-cell NHL. A higher ALC-R may predict patient
response to this treatment approach. These findings warrant
further prospective studies on rituximab-containing salvage
therapy in patients with relapsed/refractory B-cell NHL.
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